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ORIGINAL ARTICLE
Overcoming Challenges in Engineering Large,
Scaffold-Free Neocartilage with Functional Properties
Brian J. Huang, PhD,1,2 Wendy E. Brown, PhD,3 Thomas Keown, BS,4 Jerry C. Hu, PhD,3
and Kyriacos A. Athanasiou, PhD, PE3
Although numerous cartilage engineering methods have been described, few report generation of constructs greater than
4 cm2, which is the typical lesion size considered for cell-based therapies. Furthermore, current cell-based therapies only
target focal lesions, while treatment of large nonisolated lesions remains an area of great demand. The objective of this
study was to scale up fabrication of self-assembled neocartilage from standard sizes of 0.2 cm2 to greater than 8 cm2.
Passaged sheep articular chondrocytes were self-assembled into 5 or 25-mm-diameter scaffoldless neocartilage con-
structs. The 25-mm-diameter constructs grew up to 9.3 cm2 (areal scale-up of 23) and possessed properties similar to
those of the 5-mm-diameter constructs; unfortunately, these large constructs were deformed and are unusable as a
potential implant. A novel neocartilage fabrication strategy—employing mechanical confinement, a minute dead-
weight, and chemical stimulation (cytochalasin D, TGF-b1, chondroitinase-ABC, and lysyl oxidase-like 2 protein)—
was found to successfully generate large (25-mm diameter) constructs with flat, homogeneous morphologies. Chemical
stimulation increased collagen content and tensile Young’s modulus 140% and 240% in the 25-mm-diameter constructs
and 30% and 70% in the 5-mm-diameter constructs, respectively. This study not only demonstrated that exceedingly
large self-assembled neocartilage can be generated with the appropriate combination of mechanical and chemical
stimuli but also that its properties were maintained or even enhanced.
Keywords: large neocartilage, cartilage tissue engineering, cartilage repair, chondrocyte implantation, scaffold-
free cartilage, biological scale-up
Introduction
T issue engineering approaches have potential toovercome the shortcomings of clinically used cartilage
repair options. In the Unites States, an estimated 250,000
articular cartilage repair procedures are performed annual-
ly.1 Despite their prevalence, current repair therapies do not
consistently fill the entire defect, and the repair tissue pro-
duced is not hyaline and does not integrate with the sur-
rounding native tissue.
Microfracture has been shown to form a biomechanically
inferior, fibrocartilaginous repair tissue, leading to repair
tissue deterioration after 1.5–5 years.2–5 Mosaicplasty with
osteochondral autografts or allografts has been reported to
fail in 15–55% of patients after 10 years.6–8 Reasons include
failure at the osseous region, poor lateral integration, and
deterioration of graft edges. Autografts/allografts also have
a limited supply source. Finally, results from autologous
chondrocyte implantation (ACI) can be inconsistent; up to
85% of treated defects developed fibrocartilaginous fill.9–11
These inconsistencies may arise from the uncontrolled
placement of cells and an in situ neocartilage maturation
process that is dependent on patient biology and postsurgery
activities. To overcome these problems, tissue engineering
strategies need to be developed so that engineered neo-
cartilage constructs may be consistently engineered to have
functional hyaline-like matrix and with anatomically rele-
vant dimensions.
In a study investigating 25,000 knee arthroscopies, the
majority of chondral lesions (70%) were shown to be non-
isolated lesions (i.e., defined as having four or more focal
lesions).12 Treatment algorithms based on lesion size sug-
gest the use of microfracture and osteochondral autografts
for small focal lesions less than 2–2.5 cm2.8,13 Microfracture
is generally indicated for small defects, as the biomechani-
cally inferior repair tissue requires a border of native tissue
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for mechanical support. The size of osteochondral autografts
is limited to minimize donor site morbidity. Osteochondral
allografts and ACI have been recommended to treat lesions
greater than 2–2.5 cm2 8,13 and, on average, focal lesions of
4 cm2.14 Even tissue-engineered cartilage products cur-
rently in clinical trials, representing the next-generation
therapies, limit their clinical indications to focal defects
less than 7.5 cm2.15–24 Large, nonisolated defects generally
receive palliative treatment until total or partial knee ar-
throplasty is indicated. Therefore, a tissue engineering
approach that bridges the treatment of focal defects and
total joint arthroplasty remains an unmet need for the
foreseeable future. The next step in cartilage tissue engi-
neering would involve fabricating constructs not only with
functional properties but also of sufficient size to treat
cartilage lesions of all sizes.
Engineered neocartilage with hyaline-like matrix com-
position and functional biomechanical properties has been
fabricated using the self-assembling process.25,26 In the self-
assembling process, articular chondrocytes (ACs) are seeded
at high density in nonadherent agarose wells.27,28 Recently,
passaged ACs were used as a cell source in fabricating these
neocartilage constructs.25,29,30 ACs underwent chondrotun-
ing expansion29 and aggregate redifferentiation to enhance
redifferentiation of the dedifferentiated chondrocytes.30,31
With these cells, it was shown that 2 million cells per 5-mm-
diameter disc allowed the formation of homogeneous tissues
with a hyaline-like matrix (abundant type II collagen; little
to no type I collagen) and tensile properties near those of
juvenile articular cartilage.25
A significant scale-up of the self-assembling process
would be necessary to generate neocartilage constructs that
can treat all types of articular lesions. Currently, most self-
assembled neocartilage constructs may grow to at most
7 mm, or 0.4 cm2 in area. Although diffusion in the axis of
cartilage thickness may be similar in both the small and large
constructs, radial diffusion will be severely limited when
scaling up to large constructs, potentially adversely affecting
construct biomechanical properties or matrix composition.
Another challenge is maintaining shape fidelity when grow-
ing large neotissues. The logistics of creating a large con-
struct, from chondrocyte passaging to mold fabrication, may
also pose unforeseen challenges. Thus, scaling up the self-
assembling process may not be a simple or straightforward
process and should be investigated as a critical step in pushing
the technology toward broad clinical application.
Application of chemical stimuli (cytochalasin D, TGF-
b1, chondroitinase-ABC [C-ABC], and lysyl oxidase like 2
[LOXL2] protein), which had been originally developed in
5-mm-diameter self-assembled neocartilage constructs,
may not necessarily induce the same effects in scaled-up
constructs because of diffusion limitations or other un-
foreseen variables. TGF-b1 is an anabolic factor known to
promote chondrogenesis and enhance glycosaminoglycan
(GAG) and type II collagen synthesis.32,33 C-ABC acts by
temporarily depleting GAGs in the constructs, restructur-
ing the matrix to allow the development of a matrix richer
in collagens and allowing formation of thicker collagen
fibers.34 LOXL2 was not shown to affect neocartilage
matrix content, but was able to increase tissue tensile
properties by increasing the number of pyridinoline col-
lagen crosslinks.26 Cytochalasin D, a potent inhibitor of
intracellular actin stress fiber formation, has been shown to
induce a rounded cell phenotype and chondrogenesis in
stem cells.35 Although these chemical stimuli have been
shown to enhance neocartilage properties in ‘‘small’’
constructs, whether they can enhance properties in ‘‘large’’
constructs is an important criterion in successfully scaling
up the self-assembling process.
Young ACs have a superior capability to secrete cartilage
matrix molecules compared to adult chondrocytes or stem
cells that have been expanded.36 Young chondrocytes also
have significantly higher collagen II gene expression36,37
and drastically higher GAG production than adult chon-
drocytes.36,38 A cell source capable of maintaining its
chondrogenic phenotype after expansion will be critical for
the generation of functional cartilage. Allogeneic chon-
drocytes have also been shown to be nonimmunogenic.39
Currently, young allogeneic ACs have been approved for
use in cartilage repair in the form of particulated allografts
(i.e., DeNovo NT by Zimmer). The same cell source is
used by a tissue-engineered cartilage product (i.e., Reva-
Flex) currently in Phase III clinical trials. These examples
demonstrate clinical feasibility of applying young, alloge-
neic cells for cartilage repair.
The objective of this study was to scale up self-assembled
neocartilage from 0.2 cm2 to greater than 8 cm2 without
compromising the constructs’ functional properties or their
response to beneficial chemical stimulation treatment (i.e.,
cytochalasin D, TGF-b1, C-ABC, and LOXL2). The hy-
pothesis was that there would be no difference in the
functional properties between the established model of self-
assembled neocartilage formation (i.e., 5-mm-diameter con-
structs) and a significantly scaled-up version (i.e., 25-mm-
diameter constructs). Constructs of both diameters were formed
with or without chemical stimulation, and, at the end of 6 weeks
of culture, constructs were evaluated grossly, biochemically,
and mechanically. Scaling up the self-assembling process to
such a size would enable its broad use in cartilage repair by
treating a large range of lesion sizes.
Materials and Methods
Chondrogenic medium formulation
The chondrogenic medium used throughout the study com-
prised Dulbecco’s modified Eagle medium (25 mM glucose/
GlutaMAX; Thermo Fisher Scientific, Waltham, MA), 1%
(v/v) penicillin-streptomycin-amphotericin B (Lonza, Basel,
Switzerland), 1% (v/v) insulin-transferrin-sodium selenite (BD
Biosciences, San Jose, CA), 1% (v/v) NEAA (Thermo Fisher
Scientific), 100mg/mL sodium pyruvate (Thermo Fischer Sci-
entific), 50mg/mL ascorbate-2-phosphate (Sigma, St. Louis,
MO), 40mg/mL L-proline (Sigma), and 100 nM dexametha-
sone (Sigma).
Isolation of fetal sheep ACs
Fetal sheep ACs were isolated from the femoral condyle
and trochlear groove of the knees of Dorper cross sheep in
120–125 day gestation (UC Davis School of Veterinary
Medicine). Cartilage was minced into 1 mm3 cubes and was
washed with phosphate-buffered saline (PBS) before un-
dergoing digestion with 500 units/mL collagenase type 2
(Worthington Biochemical, Lakewood, NJ) in chondrogenic
LARGE, SELF-ASSEMBLED NEOCARTILAGE CONSTRUCTS 1653
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medium +3% (v/v) fetal bovine serum (FBS) (Atlanta
Biologicals, Lawrenceville, GA) for 18 h at 37C and 10%
CO2. Cells were then strained through a 70 mm filter, washed
with red blood cell lysis buffer (154.4 mM ammonium
chloride, 10 mM sodium bicarbonate, and 50 mM EDTA
tetrasodium salt in ultrapure water) for 3 min, counted, and
frozen in chondrogenic medium containing 20% (v/v) FBS
+10% (v/v) DMSO (Sigma).
Chondrocyte passaging
Primary ACs underwent chondrotuning expansion in
monolayer to passage 4 (P4), as previously described,29
with some modifications. Briefly, P0 ACs were thawed and
seeded into T225 flasks at *25,000 cells/cm2. For the first
24 h of each passage, 10% (v/v) FBS was added to the
medium to promote cell adhesion. The concentration of
FBS was then lowered to 3% (v/v) for the rest of the
passage duration. Throughout culture, the medium was
supplemented with 1 ng/mL TGF-b1, 5 ng/mL FGF-2, and
10 ng/mL platelet-derived growth factor BB (Peprotech,
Rocky Hill, NJ), also known as TFP growth factor cocktail.
The medium was changed every 3–4 days. All cultures
took place at 37C and 10% CO2. Cells were grown an
additional 4 days past 95% confluence. During passaging,
cells were lifted with an incubation in 0.25% trypsin/
EDTA (Invitrogen) for 20 min. The resulting cell solution
was then digested with 500 units/mL collagenase in
chondrogenic medium +3% (v/v) FBS for 45–60 min. Cells
were filtered through a 70 mm cell strainer, washed thrice,
counted with a hemocytometer, and either passaged again
into monolayer (as described above) or into aggregate
culture, as described next.
Aggregate culture
Passaged ACs underwent aggregate redifferentiation, as
previously described.30,31 Briefly, 10 cm petri dishes were
first coated with a thin layer of 2% molten agarose to pre-
vent cell adhesion. In each dish, 25 million cells were placed
in 25 mL chondrogenic medium supplemented with 10 ng/
mL TGF-b1, 100 ng/mL BMP-2, and 100 ng/mL GDF-5
(Peprotech). Dishes were put on an orbital shaker at 55 rpm
for 24 h and then cultured statically for an additional
13 days. Medium was changed every 2–3 days. At day 14,
cell aggregates were digested with 0.25% trypsin/EDTA for
20 min, the trypsin removed, and then digested in 500 units/
mL collagenase in chondrogenic medium +3% FBS for 90–
120 min. Cells were filtered through a 70 mm cell strainer,
washed thrice, counted, and used for the self-assembly of
neocartilage constructs.
Self-assembly of neocartilage constructs
Scaffold-free neocartilage constructs, formed by the self-
assembling process,27 were generated by seeding ACs into
2% agarose wells with an inner diameter of 5 or 25 mm.
Custom-machined, 5-mm-diameter stainless steel posts were
used as negative casts to create agarose self-assembly wells
in 750 mL of 2% agarose in each well within a 48-well plate.
Agarose wells, 25 mm in diameter, were also created using
a mold system consisting of 3D printed parts (printed with
an Objet system using MED610 or Vero White materials;
Stratasys, Eden Prairie, MN). All agarose wells were satu-
rated with several changes of chondrogenic medium for
5 days before cell seeding.
To form 5-mm-diameter neocartilage constructs, 2 mil-
lion cells in 80 mL chondrogenic medium were seeded into
empty 5-mm-diameter agarose wells. After a 4-h incubation,
500 mL medium was carefully added to each well so as to
not disturb the nascent construct (t = 0 days). Every 24 h,
500 mL medium was changed. At day 2, constructs were
unconfined and placed into 10.5-mm-diameter, 2% agarose
wells (formed by using 3D printed pegs as a negative cast)
in 24-well plates. Every 48 h, 1 mL of medium was changed.
At day 4, an agarose disc (10-mm diameter by 2-mm thick,
formed by a mold system consisting of 3D printed parts)
was added to the top of each construct, followed by addition
of an 8-mm-diameter, 7 mg plastic deadweight (taking into
account buoyancy in water; printed with MED610). The
deadweight was only applied every other day until day 21
and from days 28–35.
To form 25-mm-diameter constructs, 50 million cells in
2 mL medium were seeded into empty 25-mm-diameter
agarose wells placed on top of 3D printed plastic stands
(Fig. 1A). The agarose wells and stands were housed in 10-
cm-diameter, 2.5-cm-tall petri dishes. The plastic stands
served to enhance nutrient diffusion. After a 4-h incubation,
2 mL medium was carefully added to cover the agarose well.
A 3D printed plastic weight was placed on top of the agarose
well to prevent it from excessively moving during handling.
At day 2, constructs were unconfined and placed into 35-
mm-diameter, 2% agarose wells (formed by using a mold
system of 3D printed parts) in petri dishes. It was known
that constructs would begin developing a curled morphology
(Fig. 1B). To maintain a flat morphology, at day 4, a 33-
mm-diameter, 2.5-mm-thick agarose disc (formed by a mold
system consisting of 3D printed parts) was added to the top
of each construct, followed by addition of a 30-mm-
diameter, 175 mg plastic deadweight (taking into account
buoyancy in water; printed with MED610; Fig. 1C). The
deadweight was applied at the same temporal regimen as for
the 5-mm constructs. Every 5–6 days, 60 mL of medium was
changed.
After 42 days, constructs were photographed and their
wet weights (WW) were recorded. Each construct was then
assayed by histology, and biochemical and biomechanical
assays.
Chemical stimulation treatment
For groups subjected to chemical stimulation treatment,
2 mM cytochalasin D (Enzo Life Sciences, Farmingdale,
NY) was supplemented to the medium at days 0–3; 10 ng/
mL TGF-b1 was supplemented throughout culture (days 0–
42); and LOXL2 cocktail was supplemented at days 21–42
(LOXL2 cocktail consisted of 0.15 mg/mL lysyl oxidase-like
2 (LOXL2). Protein (Genway Bio, San Diego, CA) +1.6 mg/
mL copper sulfate (Sigma) +146 mg/mL hydroxylysine
[Sigma]); and 2 U/mL chondroitinase ABC (C-ABC; Sig-
ma), activated with 0.05 M sodium acetate (Sigma), were
applied for 4 h at day 21 (Fig. 1D). After C-ABC applica-
tion, constructs were washed with chondrogenic medium
containing 1 mM zinc sulfate (Sigma) thrice to deactivate
and remove residual C-ABC.
1654 HUANG ET AL.
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Histology and immunohistochemistry
Tissue samples (*1· 1· 1 mm) were embedded in Histo-
Prep (Thermo Fisher Scientific) and cryosectioned to 16-mm-
thick sections, and mounted on glass slides. Staining for GAGs
was performed with Safranin O, Fast Green, and Weigert’s
hematoxylin. Collagen staining was performed with Picrosir-
ius Red. Collagen I and II immunohistochemistry were also
performed, as described previously.40 Color was developed
using the Vectastain ABC reagents and DAB (Vectastain).
Biochemical analysis
Neocartilage samples, *3 · 1 · 1 mm (*5–12 mg), were
weighed to obtain WW, lyophilized for 3 days, and weighed
again to obtain dry weights. Samples were digested in digest
solution consisting of 125 mg/mL papain +5 mM N-acetyl-L-
cysteine +5 mM EDTA in phosphate buffer, pH 6.5.
Total collagen content was measured using a modified
chloramine-T colorimetric assay for hydroxyproline content.41
For each sample, 100mL of the digested engineered construct
was added to 100mL 1· tris-buffered saline, hydrolyzed with
200mL 4 N NaOH at 120C for 15 min in an autoclave, and
then neutralized with 200mL 4 N HCl. Samples were then in-
cubated with 1.25 mL of 0.062 M chloramine T (Sigma) in an
acetate-citrate buffer (0.45 M NaOH, 0.45 M sodium acetate,
0.14 M citric acid, and 0.11 M acetic acid), for 20 min at room
temperature. Samples were then incubated with 1.25 mL of
1.2 M Ehrlich’s reagent (Sigma) in 30% perchloric acid +70%
isopropanol for a 20-min incubation at 65C for color devel-
opment. Samples were plated in duplicates and absorbance
measured at 550 nm with a microplate reader. Equal amounts of
digest solution were been added to the standards (bovine col-
lagen from the Sircol Collagen Assay; Biocolor, Carrickfergus,
United Kingdom) and samples to ensure consistency.
Total sulfated GAG content was measured using the
Blyscan GAG assay kit (Biocolor) following the manufac-
turer’s instructions. Briefly, 10mL of digested sample was
incubated with 500mL dye reagent for 30 min, vortexing
periodically. The samples were centrifuged to precipitate of
the bound dye, and the pellet was dissolved in 500 mL dis-
sociated reagent. Solutions were plated to microplates and
absorbance measured at 650 nm. DNA content was assessed
with the Picogreen assay. Briefly, 10mL of the digested
sample was added to each well along with the Picogreen
reagents; fluorescence was measured at 485/528 nm Ex/Em.
Biomechanical analysis
For tensile testing, dog bone-shaped samples were cut from
each engineered construct. The dog bone samples were then
photographed and glued to paper tabs with a gauge length of
1.27 mm, and underwent uniaxial tension using an Instron
model 5565 (Instron, Canton, MA).42 A strain rate of 1% the
gauge length/s was used. Sample cross-sectional areas were
FIG. 1. Experimental timeline and setup during neocartilage culture. (A) At day 0, passage 4 chondrocytes in chondrogenic
medium + TGF-b1 + cytochalasin D were seeded into 25-mm-diameter agarose wells on top of plastic stands. The stands allowed
for better nutrient diffusion. After 4 h, during which the chondrocytes self-assembled and formed a solid construct, culture
medium (chondrogenic medium + TGF-b1 + cytochalasin D) was added to the petri dish to cover the entire agarose well. Plastic
well weights acted to prevent movement of the well during handling. At day 2, neocartilage constructs were unconfined and
transferred to 35-mm agarose wells (without a plastic stand). At day 3, cytochalasin D treatment was stopped by switching the
medium to chondrogenic medium + TGF-b1. (B, C) At day 4, neocartilage constructs were observed to exhibit curling; an
agarose disc and a deadweight were added for the purpose of maintaining a flat construct morphology. (D) Timeline of chemical
stimulation application: cytochalasin D was applied from day 0–3; TGFb-1 was applied throughout culture; LOXL2 cocktail
(LOXL2 + hydroxylysine + copper sulfate) was applied from day 21–42; C-ABC was applied for 4 h at day 21. Generation of 5-
mm constructs followed similar protocols. C-ABC, chondroitinase-ABC; LOXL2, lysyl oxidase like 2.
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calculated in ImageJ from high-resolution photographs of the
dog bone. The Young’s modulus was obtained from the linear
region of the stress-strain curve and the ultimate tensile
strength (UTS) was defined as the maximum stress obtained.
For compressive testing, a 3-mm-diameter sample was
taken from the middle of each engineered construct with a
biopsy punch. The sample was placed in a PBS bath at room
temperature and underwent unconfined stress-relaxation, as
described previously.43 Sample heights were determined by
lowering the platen until a load change of 0.02 N was de-
tected. Samples were then compressed to 10% strain at a
rate of 1% the sample height/s, held for 200 s, compressed to
20% strain, and held for 450 s. The instantaneous and re-
laxation moduli of the 20% strain curve were determined by
using a curve fit and the standard linear solid, finite defor-
mation model43 using MatLab software.
Statistics
All results were analyzed with a one-factor ANOVA and
Tukey’s post hoc test ( p < 0.05) using JMP 10 software
(SAS Institute). Data are presented as means, and error bars
represent standard deviations among biological replicates
within the same group. A sample size of n = 6–8 per group
was used. Significant differences are indicated by different
letters by each value.
Results
Neocartilage gross morphology
The gross morphological properties of the self-assembled
neocartilage constructs after 6 weeks of culture are pre-
sented in Figure 2. The 5-mm control constructs developed
bowl-shaped morphologies, as previously observed,25 while
the 5-mm stimulated constructs had flat morphologies. The
25-mm control constructs exhibited morphological defor-
mities such as wrinkles and pockets of fluid-filled cavities,
while the 25-mm stimulated constructs were flat, homoge-
neous, and solid. The 5-mm control, 5-mm stimulated, 25-
mm control, and 25-mm stimulated constructs grew to an
average of 7, 8, 34, and 32 mm in diameter. The thicknesses
of all constructs were generally slightly less than 1 mm.
Chemical stimulation reduced the thickness of both 5-mm
and 25-mm constructs, although only significantly so for the
25-mm constructs. Regional analysis of the 25-mm con-
structs showed significantly thicker edges than the center.
Histology and immunohistochemistry
Saf-O/Fast Green and Picrosirius Red staining revealed
the abundant presence of GAGs and collagen, respectively,
throughout the neocartilage constructs (Fig. 3). Differences
in staining intensity and staining distribution were not ob-
served among any groups. Immunohistochemistry revealed
presence of type II collagen throughout all constructs.
Collagen I immunohistochemical staining revealed only
trace amounts of collagen type I. Histological characteristics
qualitatively support the formation of hyaline-like cartilage
in all constructs.
Neocartilage biochemical properties
Collagen content, as measured by collagen per WW (col-
lagen/WW), was not different between the unstimulated 5-mm
and unstimulated 25-mm constructs (Fig. 4). It should be noted
FIG. 2. Gross morphology images and growth metrics of the 5- and 25-mm-diameter constructs at the end of 6 weeks of
culture. Front and side images of the 5-mm-diameter constructs, front images of the 25-mm-diameter constructs, and an
image of a U.S. quarter for comparison (A). Each tick mark on the ruler represents 1 mm. WW (B), diameter (C), and
thickness (D) of the constructs. WW, wet weight.
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that for this figure, the values of the 25-mm-diameter con-
structs represent the average values of samples from both the
center and edge regions. No difference was observed between
the stimulated 5-mm and stimulated 25-mm constructs. Che-
mical stimulation increased collagen/WW in both the 5-mm
and 25-mm constructs, but only significantly so in the 25-mm
constructs (140% increase). Collagen/WW of the edge and
center of the large constructs was similar.
GAG content, as measured by GAG/WW, was largely
unchanged between the 5-mm and 25-mm constructs in both
the control and stimulated groups. Applied chemical stim-
ulation slightly increased but did not significantly change
the GAG content of neocartilage constructs. GAG/WW of
the edge and center of the large constructs was similar.
Cellularity of the constructs, as measured by DNA/WW,
was not significantly different among all groups. Water
content, an inverse measure of the general density of the
tissue extracellular matrix, was significantly decreased by
chemical stimulation in both the 5-mm- and 25-mm-
diameter constructs, indicating that stimulation was able to
consistently increase the solid tissue density in neocartilage.
Neocartilage biomechanical properties
The tensile properties, as measured by the Young’s
modulus and the UTS, were not different between the un-
stimulated 5-mm and unstimulated 25-mm constructs
(Fig. 5). Interestingly, chemical stimulation increased the
tensile properties of the 25-mm constructs (240% increase in
Young’s modulus and 500% increase in UTS) more com-
pared with the 5-mm constructs (70% increase in Young’s
modulus and 140% increase in UTS). This led to the 25-
mm-stimulated constructs having significantly higher tensile
properties compared with the 5-mm-stimulated constructs.
The center region of the 25-mm-stimulated constructs had a
higher Young’s modulus than the edge regions, although
this trend was not seen in the UTS values.
The compressive properties, as measured by the instan-
taneous modulus and relaxation modulus, were not different
between the unstimulated 5-mm and unstimulated 25-mm
constructs. No difference was also observed between the
stimulated 5-mm and stimulated 25-mm constructs. Che-
mical stimulation significantly increased the instantaneous
modulus of the 5-mm constructs, but did not affect relaxa-
tion modulus in either the 5-mm or 25-mm constructs. The
compressive properties of the edge and center regions of
the large constructs remained largely similar; however, the
center of the 25-mm-stimulated constructs had higher in-
stantaneous modulus values than its edge.
Discussion
Toward addressing the current need to repair large or
nonisolated cartilage defects, which represent the majority
FIG. 3. Histological analysis indicates that neocartilage constructs have a matrix rich in collagen, as stained by Picrosirius
Red, and GAGs, as stained by Saf-O/Fast Green. Immunohistochemistry stains show presence of type II collagen in all
constructs with little to no type I collagen. GAG, glycosaminoglycan.
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of lesions in patients, the objectives of the study were: (1) to
fabricate scaffold-free neocartilage greater than 8 cm2 by
scaling up the self-assembling process and 2) to determine
whether the scale-up process would adversely affect neo-
cartilage properties or response to a regimen of chemical
stimuli (cytochalasin D, TGF-b1, LOXL2, and C-ABC).
The hypothesis was that neocartilage properties would not
be compromised through the scale-up process and that the
chemical stimuli would retain their beneficial effects. Ana-
lysis of construct matrix content and biomechanics supports
that the 25-mm-diameter constructs, which grew up to
9.3 cm2, possessed functional properties on par with the
small (0.4 cm2) constructs. The largest constructs generated
in the study represented a scale-up factor of 23-fold over the
FIG. 4. Biochemical and
biomechanical properties of
5-mm-diameter constructs
compared to 25-mm-
diameter constructs at the
end of 6 weeks of culture.
One sample per 5-mm-
diameter construct was eval-
uated. For 25-mm-diameter
constructs, one edge and one
center sample were pooled
per construct. Water content
(A), collagen/WW (B),
GAG/WW (C), DNA/WW
(D), tensile Young’s modulus
(E), tensile UTS (F), com-
pressive instantaneous mod-
ulus (G), and compressive
relaxation modulus (H) are
presented. Different letters
denote statistical significance
(p < 0.05) amongst groups.
UTS, ultimate tensile
strength.
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small constructs. However, without chemical stimuli, large
constructs contained folds and pockets of fluid-filled cavi-
ties, indicating that scale-up of engineered tissues remains a
challenging and nonstraightforward process.44 Through no-
vel fabrication protocols and application of chemical stim-
ulation, this study demonstrated that the 25-mm-diameter
constructs can be made into uniformly flat, homogeneously
solid neotissues, possessing properties on par with or even
higher than those of the standard 5-mm-diameter constructs.
Specifically, chemical stimulation was shown to increase
tensile Young’s modulus, UTS, and collagen/WW in the
stimulated 5-mm-diameter constructs by 70%, 140%, and 30%
over unstimulated controls; in the 25-mm-diameter constructs,
these properties were increased even further—240%, 510%,
FIG. 5. Biochemical and
biomechanical properties of
the center region compared
to the edge region of 25-mm-
diameter constructs at the
end of 6 weeks of culture, as
characterized by water con-
tent (A), collagen/WW (B),
GAG/WW (C), DNA/WW
(D), tensile Young’s modulus
(E), tensile UTS (F), com-
pressive instantaneous mod-
ulus (G), and compressive
relaxation modulus (H). Dif-
ferent letters denote statis-
tical significance (p < 0.05)
amongst groups.
LARGE, SELF-ASSEMBLED NEOCARTILAGE CONSTRUCTS 1659
D
ow
nl
oa
de
d 
by
 U
c 
Irv
in
e 
Li
br
ar
ie
s U
ni
ve
rs
ity
 o
f C
al
ifo
rn
ia
 Ir
vi
ne
 fr
om
 w
w
w
.li
eb
er
tp
ub
.c
om
 a
t 1
1/
06
/1
8.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
 
and 140%—over controls. This study showed that significant
scale-up of the self-assembling process is possible and that
neocartilage functional properties can be maintained or even
enhanced in the process. Fabrication of large functional neo-
cartilage provides a key step toward potentially treating large
or nonisolated lesions, bridging the gap between current repair
therapies and knee arthroplasty, and pushing cartilage tissue
engineering toward new possibilities.
This study represented the culmination of a series of pilot
studies with the intent to induce a flat and homogeneous
morphology in the 25-mm-diameter constructs. This was
achieved by three key processes: (1) application of chemical
stimulation, (2) unconfinement at an early time point (day
2), and (3) application of a light deadweight at day 4. The
key component within the chemical stimulation treatment
that helped prevent formation of folds and fluid-filled cav-
ities present in the control constructs was cytochalasin D.
Without cytochalasin D, control constructs were observed to
start forming folds within 24 h. Application of cytochalasin
D was observed to mitigate or delay this phenomenon until
day 2. Cytochalasin D has been shown to inhibit the for-
mation of actin stress fibers within cells, thus inducing a
rounded cell morphology and inhibiting cell migration.
The formation of internal stresses by actin stress fiber con-
traction may lead to the development of these folds within
the constructs in this study. The previously reported
chondrogenesis-inducing capabilities of cytochalasin D35,45
may also play a role encouraging a chondrogenic phenotype
in the passaged cells used within this study, resulting in
more robust neocartilage. At day 2, folds start to appear
even in the presence of cytochalasin D, possibly due to
lateral expansion of the construct as cells begin secreting an
abundance of extracellular matrix. To mitigate the devel-
opment of folds, the constructs were carefully unconfined at
day 2 (the earliest time point in which these constructs can
be handled without introducing tears) and transferred to
larger 35-mm-diameter agarose wells. At day 4, large con-
structs were observed to begin curling, indicating the for-
mation of internal stresses within the construct. These
stresses could arise for several reasons, such as incomplete
redifferentiation of chondrocytes, tightening of the contig-
uous matrix, or formation of stronger cell-matrix interac-
tions during neocartilage formation. Such phenomena need
to be elucidated in further studies. Nevertheless, to maintain
a flat morphology, the constructs were axially confined at
day 4 with the addition of an agarose disc and an exceed-
ingly light deadweight (175 mg, taking into account the
buoyancy of the plastic in fluid). In pilot experiments,
heavier weights induced construct disintegration, as the
constructs were still mechanically weak at day 4. Further-
more, to minimize potential obstruction of neocartilage
growth by the deadweight, it was removed periodically as
specified in the methods. The introduction of these steps to
an already established protocol of generating self-assembled
neocartilage, along with chemical stimulation, helped gen-
erate a flat and homogeneous morphology in the large, self-
assembled neocartilage constructs.
Due to their size, regional analysis was possible for the
25-mm-diameter constructs, while such analysis was not
possible for the 5-mm-diameter constructs. Although the
properties of the center and edge region of the large con-
structs were largely similar, some properties were different.
Specifically, the center region was significantly thinner and
exhibited significantly higher tensile Young’s modulus and
compressive instantaneous modulus than the edge region.
Greater nutrient diffusion and access to the molecules that
compose the chemical stimulation regimen may have allowed
this region to develop better properties than the slightly
thicker edges, or the 5-mm-diameter constructs overall. Pre-
vious attempts to generate large engineered cartilage con-
structs have also noted differences in properties between the
edge and center. Large agarose-embedded chondrocyte con-
structs (1.5· 1.5 cm and 2.5-mm thick), after 4 weeks of
culture, were observed visually and histologically to have
an edge region containing denser matrix than the center.44
However, quantitative biochemical or biomechanical proper-
ties of these two regions were not compared. Large constructs
(20–25 cm in diameter and 2.25-mm thick) in the shape of the
femoral head of juvenile minipigs, composed of chondrocytes
embedded in methacrylate-modified hyaluronic acid hydro-
gels, also exhibited edge effects.46 After 12 weeks of culture,
the center of the constructs had significantly lower collagen
and GAG content and mechanical properties than the edges.
The difference was attributed to potential diffusion limita-
tions. In this study, the center of the constructs did not have
inferior properties compared to those of the edge regions.
Overall, the fabrication protocols described in this study al-
lowed formation of large constructs with properties similar to
those of the small constructs.
This study demonstrated the feasibility of generating
functional neocartilage greater than 8 cm2 without compro-
mising its properties. These constructs can potentially be
used to treat a broader range of cartilage lesion sizes com-
pared to current therapies. Among current cartilage repair
options, microfracture or osteochondral autografts have
been stated to optimally treat lesions less than 2–2.5 cm2 in
area.8,13 Above this size, cell-based therapies, such as ACI,
tissue-engineered products, and osteochondral allografts,
have been used to treat focal defects that are generally less
than 7.5 cm2 14–24; the average size of lesions treated by ACI
and osteochondral allografts is 4 cm2.14 However, 70% of
cartilage lesions have been shown to be nonisolated le-
sions,12 which often exceed sizes larger than 7.5 cm2. The
large constructs generated in this study did not exhibit sig-
nificant decreases in biochemical or functional biomechan-
ical properties; in fact, some properties were enhanced
during scale-up. With the current demonstration that such
large neocartilage constructs can be fabricated, the next
developmental phase would be to create anatomically cor-
rect morphologies. Functional neocartilage of these sizes
can potentially treat large or nonisolated lesions. Repair
therapy using these scaled-up constructs can potentially
bridge the gap between current therapies that only treat focal
defects and total or partial knee arthroplasty.
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